Introduction
============

Pancreatic cancers are increasing in frequency, representing the fourth most common cancer in the United States and globally the seventh most malignancy [@B1]. Peak incidence of the disease is in the sixth and seventh decades of life. Causes of pancreatic cancer are unknown, but it is associated with chronic pancreatitis and diabetes [@B2], [@B3]. Genomic abnormalities include frequent mutations of KRAS, TP53, CDKN2A, and SMAD4 [@B4]-[@B7]. Genetic alteration in a core set of 12 cellular signaling pathways (60-100%) are involved in pancreatic cancer [@B8]. Pancreatic cancer has a high mortality rate and ninety-five percent of patients die within five years. No biomarkers for early diagnosis are available; and at diagnosis, the disease is usually no longer curable by surgery. Chemotherapy with either gemcitabine or in combination with other drugs (e.g. paclitaxel, erlotinib) has limited activity against this cancer [@B9], [@B10]. Multi-targeted kinase inhibitor dasatinib retards growth of human pancreatic adenocarcinoma cells in an orthotopic nude murine model [@B11] and inhibits metastasis in a murine model of pancreatic ductal adenocarcinoma [@B12].

We previously identified dasatinib-sensitive and -resistant pancreatic cancer cell lines [@B13]. In that study, a panel of human pancreatic cancer cell lines was screened with dasatinib plus 65 kinase inhibitors. At the highest concentration of dasatinib (1 μM), 9 cell lines (AsPc1, CFPAC, BxPc3, MiaPaCa2, Panc0203, Panc0327, Panc1, SU8686, PL45) did not achieve an IC50 (defined as dasatinib-resistant). Six cell lines (HPAC1, Panc0403, Panc0504, Panc1005, Panc0813, CaPan2) had IC50 of dasatinib between 20 - 250 nM (defined as dasatinib-sensitive). Here, we used an unbiased screening of dasatinib-resistant pancreatic cancer cells (SU8686) with a genome-wide shRNA library followed by massively parallel sequencing to identify novel targets and signaling pathways that can potentiate synergistic inhibitory effects of dasatinib. We identified inhibitors of the FOXO and hedgehog families, histone deacetylases, as well as XPO1 (nuclear protein exporter) which markedly enhanced ability of dasatinib to suppress cellular proliferation of pancreatic cancer cells.

Materials and Methods
=====================

shRNA library screen
--------------------

We used MISSION LentiPlex Human Pooled shRNA Library SHP001 containing more than 75,000 shRNA constructs targeting 15,000+ human genes (Sigma, St. Louis, MO) (Supplementary Figure [1](#SM0){ref-type="supplementary-material"}). At day 0, human pancreatic cancer cell line SU8686 was seeded in 150 mm tissue culture dishes at a density that by the next day the cells were between 30 to 40% confluent. At day 1, the cells were infected with lentivirus for 24 hr. Viral titer of 0.3 MOI (multiplicity of infection) was used to obtain a single viral infection per cell. At day 2, the virus was removed and replaced with regular culture medium. At day 3, cells were incubated under selection with puromycin (5 μg/ml, 48h). At day 5, culture medium containing puromycin was removed and replenished with fresh medium without puromycin. At day 7, cells reached confluence and were passaged at 1:4 for subsequent dasatinib treatment and 1:8 for controls. At day 8, dasatinib (10 ng/ml) was added to the cells. After 5 days of incubation, both control and dasatinib-treated plates reached confluence, and cells were harvested for genomic DNA using QiaAMP DNA micro kit (Qiagen, Valencia, CA). Hairpins from genomic DNA were retrieved with PCR (forward primer: ATCTTGTGGAAAGGACGAAAC; reverse primer: ACCTCGAGACAAATGGGCAGTA) and 114 bp products were purified for deep sequencing with SOLEXA (Illumina, San Diego, CA). Sequencing and data analyses were performed at the Core Facility in National University of Singapore. (Supplementary Figure [S2](#SM0){ref-type="supplementary-material"}).

Databases
---------

Public databases used included RIGER (<http://www.broadinstitute.org/cancer/software/GENE-E/>), PANTHER (protein analysis through evolutionary relationships) classification system (<http://www.pantherdb.org/>), Oncomine (<http://www.webcitation.org/>), and Pathway interaction database (PID) (<http://pid.nci.nih.gov/>). For RIGER analysis, Second Best Rank feature was used; shRNAs were selected when at least two different shRNAs had the same effect.

Real-time PCR
-------------

Total RNA was isolated with TRIZOL (Life Technologies, Carlsbad, CA) and cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Carlsbad, CA) according to manufacturers\' instructions. Detection of gene expression was performed on Applied Biosystems 7500 Fast real-time PCR system (Life Technologies, Carlsbad, CA). Expression levels of mRNA were normalized to β-actin and expression of MAX in SU8686 was designated at 1.

MTT assay
---------

Human pancreatic cancer cells (3x10^3^ per well in 96 well plates) were incubated with drugs for 72h, and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma-Aldrich, St. Louis, MO) was used to assess cell viability. For drug combination, drugs were added simultaneously to cells and incubated for 72h and assayed with MTT. Lipofectamine RNAiMAX (Life Technologies, Carlsbad, CA) was used for siRNA transfection. Forty-eight hours after transfection, cells were incubated with drugs for 72h. Combination index (CI) was calculated using Calcusyn [@B14]. Values of CI indicate synergistic (\<1), additive (=1), or antagonistic (\>1) effect. Calculation of IC50 was based on sigmoidal dose-response curve fitting, using Graphpad prism (La Jolla, CA). Hypoxic experiments were carried out in temperature-controlled hypoxia chamber at 2% O~2~, 5% CO~2~, 93% N~2~. Data represent means ± standard deviations of either two or three independent experiments with quadruplicate wells per experiment.

Colony formation assay
----------------------

For clonal growth on plastic, cells were seeded at a density that resulted in 30-40% confluence in 6-well plates on the following day. For colony formation in soft agar, 3,000 cells were seeded in the top layer of 0.25% agar with a bottom layer of 0.5% agar. After addition of drugs, the plates were incubated for 14 days. Cells were stained with 0.1% crystal violet and photographed. Number of colonies was counted with ImageJ (<http://imagej.nih.gov>). Data represent the average of two independent experiments each done with triplicate wells.

Animal studies
--------------

All animal studies were in accordance with protocols approved by Institutional Animal Care and Use Committee (IACUC) at National University of Singapore. The human pancreatic cancer cells (MiaPaCa2, 10^7^ cells) were injected subcutaneously into six-week-old NSG mice. Mice were randomly divided into four groups: 1. Oral treatment with KPT-330 (selinexor) (Karyopharm Therapeutics, Newton, MA) (10mg/kg); 2. Intraperitoneal injection with dasatinib (10mg/kg); 3. Treatment with both KPT-330 and dasatinib; 4. Diluent control. Each mouse carried 1 tumor with 6 mice per group. The mice received the drug/diluent control three times per week for 4 weeks. During the study, mice were supplemented with Nutri-cal (Tomlyn, Fort Worth, TX). Tumor size and body weight were measured weekly. Tumor volume was calculated using the formula: volume (mm^3^) = (long diameter) x (short diameter)^2^ /2. At the end of experiments, the tumors were carefully dissected and weighed. Blood chemistries (ALB, GLU, TP, CREA, BUN, AST and ALT) and complete blood cell counts were measured. Organ weights (liver, kidney, spleen) were measured. Portions of the tumors were used for immunohistochemistry (IHC) to examine levels of Ki-67 (ab15580, Abcam, Cambridge, UK) and phosphorylated ERK1/2 (\#4376, Cell Signaling, Danvers, MA). IHC was performed as previously described [@B15].

Western blot analysis
---------------------

Protein lysates were extracted from cells with RIPA lysis buffer (ThermoScientific, Rockford, IL) and resolved with SDS-PAGE. Following transfer to PVDF membrane, antibodies from Cell Signaling (Danvers, MA), Santa Cruz (Santa Cruz, CA), or Sigma-Aldrich (St. Louis, MO) were used to examine protein expression.

Results
=======

Genome wide screening for modulators of dasatinib response
----------------------------------------------------------

A pooled library containing \~75,000 shRNAs targeting \~15,000 genes was used to screen for synthetic lethal siRNAs in the dasatinib-resistant human pancreatic cancer cell line SU8686. By employing the screening strategy (Supplementary Figure [S1](#SM0){ref-type="supplementary-material"}), we identified genes that when suppressed, potentiated the activity of dasatinib to induce cell death of SU8686 pancreatic cancer cells. RIGER analysis showed 729 depleted shRNAs targeting 410 genes with a high hairpin score (\> 0.2) at a significant level (p \< 0.05) for dasatinib treated cells (Supplementary Table [S1](#SM0){ref-type="supplementary-material"}). These 410 genes may be targets for overcoming dasatinib resistance in pancreatic cancer cells. Conversely, 616 amplified hairpins targeting 350 genes in dasatinib treated cells had enhanced shRNA suggesting that these silenced genes may be pro-proliferative in the presence of dasatinib.

The 410 genes from the primary screen were categorized by PANTHER (protein analysis through evolutionary relationships) classification system. Twelve biological processes were enriched in relation to dasatinib resistance (Supplementary Figure [S3](#SM0){ref-type="supplementary-material"}). Not surprisingly, "metabolic process" was over-represented (182 genes) since metabolic phenomena related to chemo-resistance is well established. Genes attributed to the "apoptotic process" (16 genes) and "response to stimulus" (46 genes) were likewise represented. Pathway analysis of these 410 genes using PID (pathway interaction database) indicated multiple pathways were related to dasatinib-resistance (Table [1](#T1){ref-type="table"}). Notably XPO1 (nuclear protein exporter) was involved in several pathways including signaling through FOXO, hedgehog, and canonical NF-κB as well as signaling events mediated by HDAC class 1 (Table [1](#T1){ref-type="table"}). XPO1 and other key components of these pathways may be targeted for potential synergistic effects with dasatinib.

Targeting HDAC signaling enhanced dasatinib killing of pancreatic cancer cells
------------------------------------------------------------------------------

Silencin the HDAC pathway enhanced dasatinib activity. In our previous studies, we have shown anti-proliferative activity of HDAC inhibitors (belinostat, panobinostat, vorinostat) against pancreatic cancer cells [@B16], [@B17]. Effect of interaction between these inhibitors and dasatinib was examined in six pancreatic cancer cell lines (SU8686, Panc0203, Panc1005, BxPc3, MiaPaCa2, Panc1) (Figure [1](#F1){ref-type="fig"}). Cell proliferation was synergistically inhibited in the presence of dasatinib at low concentrations (25 or 100 nM) and each of the three HDAC inhibitors against SU8686, Panc1005, Panc0203, BxPc3, MiaPaCa2, and Panc1 (Table [2](#T2){ref-type="table"}). These results suggested that concomitant inhibition of HDAC signaling may be an effective complement to dasatinib in pancreatic cancers.

Components (MAX, SAP18, XPO1) of the HDAC signaling pathway were identified from our synthetic lethal screening assay (Table [1](#T1){ref-type="table"}). These genes were over-expressed in tumors compared to normal pancreas using public data databases (Supplementary Figure [S4](#SM0){ref-type="supplementary-material"}A). High expression of XPO1 was associated with high risk pancreatic cancers (Supplementary Figure [S4](#SM0){ref-type="supplementary-material"}B). Endogenous expression levels of these genes in the pancreatic cancer cell lines did not correlate with their sensitivities to dasatinib (Supplementary Figure [S5](#SM0){ref-type="supplementary-material"}). Howeve, pancreatic cancer cell lines (SU8686, MiaPaCa2, Panc1, BxPc3, Panc0203, Panc1005) with silencing of both MAX (siMAX) and XPO1 (siXPO1) inhibited cell growth in pancreatic cancer cells compared to control cells (siCON) (Figure [2](#F2){ref-type="fig"}A). Additionally, the IC50 of dasatinib against pancreatic cancer cell lines was lower if these cells also had silencing of either MAX or XPO1 compared to controls (siCON) (Figure [2](#F2){ref-type="fig"}B). For example, the IC50 of dasatinib against the SU8686 cells was 2.5 x 10^-5^ M; but with silencing of either MAX or XPO1, the IC50 of dasatinib decreased to 2.3 x10^-6^ M and 4.3 x 10^-7^ M, respectively (Figure [2](#F2){ref-type="fig"}B). These observations indicate that silencing the HDAC pathway (e.g. MAX and XPO1) enhances the ability of dasatinib to inhibit proliferation of pancreatic cancer cell.

Effect of XPO1 inhibitor KPT-330 (selinexor) in pancreatic cancer cells
-----------------------------------------------------------------------

Because knockdown of XPO1 by siRNA inhibited pancreatic cancer cell proliferation, the anti-tumor activity of three XPO1 inhibitors (KPT-185, -276, -330) was investigated. Several pancreatic cancer cell lines were sensitive to these inhibitors at an IC50 from 1 x 10^-7^ to 1 x 10^-5^ M (Table [3](#T3){ref-type="table"}). KPT-330 (selinexor) is undergoing clinical trials for various cancers including T cell leukemia and solid tumors [@B18]. Seven pancreatic cancer cell lines (SU8686, MiaPaCa2, Panc1, BxPc3, Panc0203, Panc1005, Panc0813) were sensitive to KPT-330 (selinexor) (Table [3](#T3){ref-type="table"}). KPT-330 (selinexor) decreased clonal growth of pancreatic cancer cell lines (MiaPaCa2, Panc1) on plastic (Figure [3](#F3){ref-type="fig"}A). Likewise, anchorage-independent growth of these cells progressively decreased with increasing concentration of KPT-330 (selinexor) (1 to 10 μM) (Figure [3](#F3){ref-type="fig"}B). These results showed that KPT-330 (selinexor) effectively inhibited growth of pancreatic cancer cells.

Incubation of pancreatic cancer cells (MiaPaCa2, Panc1) with KPT-330 (selinexor) (10 μM, 36 hr) decreased levels of XPO1, increased the apoptotic-related proteins BIM and BAX, but did not change the expression of the anti-apoptotic proteins BCL-2 or BCL-XL (Figure [4](#F4){ref-type="fig"}A). Protein levels of proliferation-related proteins, MYC and SURVIVIN, also decreased (Figure [4](#F4){ref-type="fig"}A). Because dasatinib is a multi-target ATP-competitive kinase inhibitor, we investigated the phosphorylation levels of 4 kinases (pSRC, pFAK, pERK, pAKT) since these 4 kinases are highly activated in human pancreatic cancer. Single agent dasatinib suppressed pSRC but KPT-330 did not. Combination of both dasatinib and KPT-330 slightly enhanced the suppression of pSRC (Figure [4](#F4){ref-type="fig"}B). Dasatinib did not inhibit pFAK but KPT-330 did. Combination treatment of dasatinib and KPT-330 showed enhanced inhibition of pFAK (Figure [4](#F4){ref-type="fig"}B). KPT-330 down-regulated pAKT and combined therapy prominently enhanced the down-regulation (Figure [4](#F4){ref-type="fig"}B). Either dasatinib or KPT-330 alone suppressed pERK1/2 and their combination enhanced suppression of pERK1 (Figure [4](#F4){ref-type="fig"}B). Taken together, combination of KPT-330 plus dasatinib enhanced de-phosporylation of the SRC, AKT, ERK, and FAK kinases.

Sensitivity of pancreatic cancer cells to the combination of KPT-330 (selinexor) and dasatinib
----------------------------------------------------------------------------------------------

The ability of KPT-330 (selinexor) to potentiate the anti-tumor activity of dasatinib in pancreatic cancer cells was evaluated. Three pancreatic cancer cell lines (SU8686, MiaPaCa2, Panc1) were treated with either KPT-330 (selinexor) (0.01-10 μΜ), dasatinib (1-1000 nM) or a combination of both drugs (Figure [5](#F5){ref-type="fig"}A). The combination of both drugs synergistically decreased the pancreatic cancer cells as shown by their combination indices (CI) (Figure [5](#F5){ref-type="fig"}B). Xenografts using human pancreatic cancer cells MiaPaCa2 were established in NSG mice to evaluate the efficacy of the combination of KPT-330 (selinexor) and dasatinib *in vivo*. KPT-330 (selinexor) treatment by itself reduced average tumor weight from a mean of 0.252 ± 0.093 to a mean of 0.095 ± 0.030 grams compared to diluent control (*p*\<0.01, Figure [6](#F6){ref-type="fig"}A). Average tumor weight with dasatinib treatment alone was 0.228 ±0.098 g; and in combination with KPT-330 (selinexor) the average tumor weight diminished to 0.048 ± 0.023 grams (*p*\<0.05, Figure [6](#F6){ref-type="fig"}A). No significant change in either body weight or blood chemistry parameters occurred with drug treatments (Supplementary Figure [S6](#SM0){ref-type="supplementary-material"}). To investigate further the characteristics of tumors, the levels of cell proliferation (Ki-67) and phosphorylation levels of ERK1/2 were examined by IHC. Compared with control xenografts, a decreased cell proliferation (Ki-67) and phosphorylation of ERK1/2 was detected in xenografts from mice receiving the combined treatment of KPT-330 and dasatinib (Figure [6](#F6){ref-type="fig"}B). Likewise, the combination of KPT-330 and dasatinib decreased growth of the xenografts (Figure [6](#F6){ref-type="fig"}B).

Discussion
==========

Although dasatininb has some efficacy against pancreatic cancer, the majority of patients are either refractory to this therapy or quickly acquire resistance during treatment. Thus pancreatic cancer remains a clinical challenge if it cannot be cured by surgery. Using a large shRNA library screen and next-generation sequencing as a platform, 729 depleted shRNAs corresponding to 410 genes were identified in the dasatinib treated cells. Pathway analysis suggested targeting mTOR signaling (*p* = 0.000126), hedgehog signaling (*p* = 0.001), FOXO family (*p* = 0.001), or canonical NF-κB pathway (*p* = 0.049) may prominently inhibit pancreatic cancer cell proliferation when combined with dasatinib. We particularly focused on the synthetic lethal interaction between dasatinib and an inhibitor of either HDAC or XPO1.

HDAC inhibitors result in acetylation of both histones and proteins. For examples, acetylation of histone 3 lysine 27 is associated with increase gene expression. Acetylation of p53 enhances its activity to slow growth or induce apoptosis. HDAC inhibitors have shown anti-tumor activity against various cancer types including pancreatic cancer [@B17], [@B19]. We found that pharmacological levels of HDAC inhibitors in combination with dasatinib markedly suppressed human SU8686 pancreatic cancer cells even in the presence of a very low concentrations of dasatinib (25 or 100 nM). For other pancreatic cancer cell lines (BxPc3, Panc0203, MiaPaCa2, Panc1), similar but less robust anti-pancreatic cancer growth was noted with the combination of dasatinib and HDAC inhibitors.

One component required for signaling by HDACs as well as FOXO and canonical NF-κB involves transport across the nuclear membrane through XPO1 [@B20], [@B21]. Leptomycin B, an inhibitor for XPO1, was found to have anti-cancer activity but caused too much systemic toxicity [@B22]. This prompted the synthesis and development of a series of selective inhibitors of nuclear export (SINE) \[KPT-185, -276, and -330\] which have anti-proliferative activity against a wide variety of cancers including ovarian cancer [@B23], hepatocellular carcinoma [@B24], lung cancer [@B25], and several haematological malignancies [@B26]. KPT-330 (selinexor) has been and is used in several clinical trials in solid and hematopoietic malignancies including acute myeloid leukemia [@B27], [@B28], multiple myeloma [@B29], chronic myelogenous leukemia, and non-Hodgkin lymphoma [@B30] . Many key proteins (e.g. FOXOs, NPM, and p53) are aberrantly localized or altered in their abundance by this family of inhibitors [@B31]-[@B33]. Functionally, we showed that pancreatic cancer cells were sensitive to KPT-185, -276, and -330; and furthermore, the anticancer potency of KPT-330 (selinexor) was enhanced in hypoxic conditions (the normal condition of pancreatic cancer cells) (Supplementary Figure [S7](#SM0){ref-type="supplementary-material"}). KPT-330 (selinexor) suppressed colony formation of pancreatic cancer cells *in vitro* as well as those growing as xenografts in immuodeficient mice corroborating a previous study [@B21]. More importantly, KPT-330 (selinexor) over a wide range of concentrations was synergistic with dasatinib, the multi-targeted kinase inhibitor in their anti-proliferative activity against pancreatic cancer cells both *in vitro* and in a xenograft model. KPT-330 also synergized with gemcitabine in human pancreatic cancer cell lines (Supplementary Figure [S8](#SM0){ref-type="supplementary-material"}), corroborating a previous study [@B34]. In this study, KPT-330 up-regulated apoptotic molecules and down-regulated anti-apoptotic molecules in pancreatic cancer cells. The combination of dasatinib plus KPT-330 markedly decreased the phosphorylation of SRC, FAK, ARK, and ERK kinases.

Incidence of pancreatic cancer is increasing globally and an efficient non-surgical therapeutic treatment of is urgently needed. Phase I study of dasatinib when combined with gemcitabine showed partial response in 25% of patients [@B35] and phase II study indicates dasatinib does not have clinical activity as a single agent in metastatic pancreatic cancer [@B36]. Recent pre-clinical studies suggest targeting TGFβ together with dasatinib may be a novel therapeutic approach for pancreatic cancer [@B37], [@B38]. In this study, we identified two pathways that mediated synthetic lethality with dasatinib. The first is HDAC inhibitors which have been approved by the FDA for other cancers. The second is KPT-330 (selinexor) which blocks protein and RNA transport from the nucleus. The key anti-cancer targets of the drug are probably multiple; we showed that two pro-apoptotic proteins (BAX, BIM) markedly increased, while anti-apoptotic protein (SURVIVIN) as well as the pro-growth protein (MYC) decreased in the pancreatic cancer cells. In summary, either HDAC inhibitors or KPT-330 (selinexor) combined with dasatinib appeared should be explored in surgically failed pancreatic cancers.

Supplementary Material {#SM0}
======================

###### 

Supplementary figures and tables.

###### 

Click here for additional data file.

This work was funded by the Singapore Ministry of Health\'s National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award to H. Phillip Koeffler, the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative. This study was partially supported by a generous donation from the Melamed family and the Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center through the Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy Project\".

![**Effect of combination of dasatinib with various HDAC inhibitors on cell proliferation of pancreatic cancer cells.** Six human pancreatic cancer cell lines (SU8686, BxPc3, MiaPaCa2, Panc0203, Panc1, Panc1005) were treated with either single drug dasatinib, HDAC inhibitor (belinostat, panobinostat, vorinostat) or combination of both at various concentrations for 72h. Cell viability was measured (MTT assay); and data were normalized to controls without drug treatment. Das, dasatinib; Bel, belinostat; Pan, panobinostat; SAHA, vorinostat.](jcav09p4762g001){#F1}

![**Effect of siRNA-mediated gene silencing of either MAX or XPO1 on human pancreatic cancer cell proliferation and dasatinib sensitivity.** Six human pancreatic cancer cell lines (SU8686, MiaPaCa2, Panc1, BxPc3, Panc0203, Panc1005) were transfected with siRNAs against either MAX or XPO1 (siMAX or siXPO1) and treated with dastainib (10^-9^ - 10^-6^ M). A. Without dasatinib treatment, proliferation of siMAX-transfected and siXPO1-transfected cells was compared to siCON-transfected cells by MTT assays. B. siRNA transfected cells were treated with dasatinib (10^-9^ - 10^-6^ M), and cell viability was measure by MTT assays. For each cell line, cell growth was normalized to itself without dasatinib treatment. \*Values of IC50 were extrapolated from dose curves using Graphpad Prism software.](jcav09p4762g002){#F2}

![**KPT-330 activity against human pancreatic cancer cells.** A. Two pancreatic cancer cell lines (MiaPaCa2, Panc1) were treated with KPT-330 (10 μM) for 14 days, and the number of colonies present on plastic were counted and plotted on bar graphs (described in Materials and Methods). B. Soft agar colony formation with KPT-330 treatment. Two pancreatic cancer cell lines (MiaPaCa2, Panc1) were grown in soft agar with KPT-330 (1 or 10 μM) for 14 days. Colonies were stained and counted as shown in bar graphs (described in Materials and methods). \*\*: *p* \< 0.01; \*\*\*: *p* \< 0.001.](jcav09p4762g003){#F3}

![**Cooperative effect of KPT-330 and dasatinib on cell signaling.** A. Western blot analysis of pancreatic cancer cells (MiaPaCa2, Panc1) treated with KPT-330 (10 μM, 36h). Changes in expression of XPO1 as well as proteins related to cell proliferation and apoptosis (BIM, BAX, BCL2, BCL-XL, MYC, SURVIVIN). B. MiaPaCa2 pancreatic cancer cell line was treated with dasatinib (200 nM) and/or KPT-330 (10 μM) for 16 h. Phosphorylation levels of SRC, FAK, AKT, and ERK1/2 were detected by Western blot analysis. Actin was used as loading control. pSRC, phosphorylated SRC; pFAK, phosphorylated FAK; pAKT, phosphorylated AKT; pERK1/2, phosphorylated ERK.](jcav09p4762g004){#F4}

![**Growth of pancreatic cancer cells in the presence of the combination of the XPO1 inhibitor (KPT-330) with dasatinib.** A. MTT assays of three pancreatic cancer cell lines (SU8686, MiaPaCa2, Panc1) treated with either single drug (KPT-330 or dasatinib) or a combination of both. Cell viability was normalized to control without drug treatment. Das: dasatinib. B. Combination index (CI) was calculated for the drug combinations with Calcusyn as described in Materials and Methods. CI value \> 1 (antagonist), = 1 (additive effect), \< 1 (synergism).](jcav09p4762g005){#F5}

![**KPT-330 was synergistic with dasatinib in the inhibition of pancreatic tumor growth *in vivo***. MiaPaCa2 cells were injected subcutaneously in immunodeficient mice. After the tumors became palpable, mice were treated with KPT-330 (10 mg/kg by oral gavage), dasatinib (10 mg/kg intraperitoneally), combination of KPT-330 and dasatinib, or diluent control, as described in Materials and Methods. A. At the end of the experiments, tumors were weighed. Student *t*-test was used to compare the difference among the tumors. ns: nonsignificant; \*: *p* \< 0.05; \*\*: *p* \< 0.01. B. Immunohistochemical staining with Ki-67 and phosphorylated ERK (pERK) on xenografts. Image magnification, 20x; scale bar, 100 μm. Representative slides are shown.](jcav09p4762g006){#F6}

###### 

Potential targeted pathways\*

  Pathway Name                                                     Genes depleted in experimentals                  *p*-value
  ---------------------------------------------------------------- ------------------------------------------------ -----------
  FAS (CD95) signaling pathway                                     FADD, FAIM2, FASLG, MAPK10, PDK1, PDPK1          3.5E-05
  mTOR signaling pathway                                           KRAS, MAP2K1, PDK1, PDPK1, RAF1, SGK1, YWHAZ     1.3E-04
  ATM pathway                                                      ATM, BLM, CDC25C, FAM175A, TOP3A                 2.0E-04
  GMCSF-mediated signaling events                                  KRAS, MAP2K1, PIM1, RAF1, YWHAZ                  2.7E-04
  Trk receptor signaling mediated by PI3K and PLC-gamma            KRAS, PDK1, PDPK1, TRPV1, YWHAZ                  3.0E-04
  CXCR3-mediated signaling events                                  KRAS, MAP2K1, PDK1, PDPK1, RAF1                  0.001
  TCR signaling in naïve CD4+ T cells                              CSK, DBNL, HLA-DRA, KRAS, PDK1, PDPK1            0.001
  Signaling events mediated by HDAC Class I                        LOC729458, MAX, MBD3L2, SAP18, WDR77, XPO1       0.001
  Hedgehog signaling events mediated by Gli proteins               MAP2K1, MTSS1, SAP18, SPOP, XPO1                 0.001
  FoxO family signaling                                            FASLG, MAPK10, SGK1, XPO1, YWHAZ                 0.001
  Ras signaling in the CD4+ TCR pathway                            KRAS, MAP2K1, RAF1                               0.001
  IGF1 pathway                                                     PDK1, PDPK1, RAF1, YWHAZ                         0.001
  ErbB1 downstream signaling                                       KRAS, MAP2K1, PDK1, PDPK1, RAF1, SH2D2A, YWHAZ   0.002
  Trk receptor signaling mediated by the MAPK pathway              KRAS, MAP2K1, RAF1, TRPV1                        0.002
  Class I PI3K signaling events mediated by Akt                    PDK1, PDPK1, RAF1, YWHAZ                         0.003
  PLK3 signaling events                                            ATM, CDC25C                                      0.004
  PDGFR-beta signaling pathway                                     CSK, KRAS, MAP2K1, MAPK10, RAF1, SIPA1, YWHAZ    0.004
  BCR signaling pathway                                            CSK, MAP2K1, PDK1, PDPK1, RAF1                   0.004
  Regulation of Telomerase                                         ATM, BLM, MAX, POT1, SAP18                       0.005
  ErbB2/ErbB3 signaling events                                     KRAS, MAP2K1, MAPK10, RAF1                       0.005
  Downstream signaling in naïve CD8+ T cells                       FASLG, GZMB, KRAS, MAP2K1, RAF1                  0.005
  CXCR4-mediated signaling events                                  CSK, HLA-DRA, ITGA6, PDK1, PDPK1, VPS4B          0.006
  Signaling events mediated by VEGFR1 and VEGFR2                   MAP2K1, PDK1, PDPK1, RAF1, SH2D2A                0.006
  LKB1 signaling events                                            ETV4, MAP2, SIK1, YWHAZ                          0.007
  Fanconi anemia pathway                                           ATM, BLM, FANCE, TOP3A                           0.007
  Class I PI3K signaling events                                    KRAS, PDK1, PDPK1, SGK1                          0.007
  Signaling events mediated by Stem cell factor receptor (c-Kit)   MAP2K1, PDK1, PDPK1, RAF1                        0.010
  IL8- and CXCR1-mediated signaling events                         CXCR1, PDK1, PDPK1                               0.011
  C-MYB transcription factor network                               GSTM1, KRAS, MAD1L1, PIM1, SKI                   0.011
  TCR signaling in naïve CD8+ T cells                              CSK, KRAS, PDK1, PDPK1                           0.012
  Caspase Cascade in Apoptosis                                     FADD, FASLG, GZMB, SPTAN1                        0.012
  Alpha6 beta4 integrin-ligand interactions                        ITGA6, LAMA1                                     0.013
  HIV-1 Nef: Negative effector of Fas and TNF-alpha                FADD, FASLG, TRAF1                               0.017
  IL8- and CXCR2-mediated signaling events                         CXCR2, PDK1, PDPK1                               0.017
  IL12-mediated signaling events                                   CCL3, FASLG, GZMB, HLA-DRA                       0.020
  Insulin Pathway                                                  PDK1, PDPK1, SGK1                                0.032
  Signaling events mediated by c-Met                               MAP2K1, PDK1, PDPK1, RAF1                        0.034
  a6b1 and a6b4 Integrin signaling                                 ITGA6, LAMA1, YWHAZ                              0.034
  Ceramide signaling pathway                                       FADD, MAP2K1, RAF1                               0.039
  p38 signaling mediated by MAPKAP kinases                         RAF1, YWHAZ                                      0.042
  Canonical NF-kappaB pathway                                      ATM, XPO1                                        0.049

\*Potential target pathways were determined using NCI pathway interaction database.

###### 

Analysis of drug interaction between dasatinib and HDAC inhibitors

  Das (nM)   Bel (nM)   Pan (nM)   SAHA (nM)   CI                                 
  ---------- ---------- ---------- ----------- ------ ------ ------ ------ ------ ------
  25         250        \-         \-          0.56   1.33   0.67   0.8    \-     \-
  100        1000       \-         \-          0.87   1.8    1.11   0.86   \-     \-
  400        4000       \-         \-          1.6    0.7    1.98   1.87   \-     \-
  25         \-         25         \-          0.75   1.3    0.73   1.92   \-     \-
  100        \-         100        \-          0.61   1.83   0.79   0.95   \-     \-
  400        \-         400        \-          2.03   0.98   2.01   2.13   \-     \-
  25         \-         \-         250         0.52   1.12   0.41   2.87   \-     \-
  100        \-         \-         1000        0.97   3.16   1.27   0.79   \-     \-
  400        \-         \-         4000        1.14   0.62   2.12   1.74   \-     \-
  100        100        \-         \-                 \-     \-     \-     0.93   0.84
  100        1000       \-         \-                 \-     \-     \-     1.27   0.8
  100        \-         10         \-                 \-     \-     \-     3.23   2.16
  100        \-         100        \-                 \-     \-     \-     2.14   1.84

CI (Combination index) was calculated with Calcusyn as described in Materials and Methods. Additive effect (CI = 1), synergism (CI \< 1), antagonist (CI \>1). Das: dasatinib; Bel: belinostat; Pan: panobinostat; SAHA: vorinostat. Synergy is highlighted in red.

###### 

Anti-tumor activity of XPO1 inhibitors against pancreatic cancer cells (IC50\*, M)

             KPT-185        KPT-276        KPT-330
  ---------- -------------- -------------- --------------
  SU8686     3.5 x 10^-6^   6.7 x 10^-6^   9.2 x 10^-7^
  MiaPaCa2   2.4 x 10^-6^   1.1 x 10^-5^   7.2 x 10^-7^
  Panc1      1.1 x 10^-6^   2.9 x 10^-6^   1.1 x 10^-6^
  BxPc3      9.6 x 10^-6^   1.6 x 10^-5^   1.2 x 10^-5^
  Panc0203   R              2.2 x 10^-5^   5.6 x 10^-6^
  Panc1005   1.5 x 10^-6^   1.3 x 10^-5^   1.3 x 10^-6^
  Panc0813   1.7 x 10^-6^   2.3 x 10^-6^   4.1 x 10^-7^
  AsPc1      2.9 x 10^-5^   R              R

Cell lines were cultured with three XPO1 inhibitors for 72 and cell viability was measured by MTT assay. \*IC50s were extrapolated from MTT data using Graphpad Prism software as described in Materials and Methods. R: resistant.
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